Shares of Suven Life Sciences hit the upper circuit at 20 per cent to close at Rs 16.92 on the completion of phase-I trials of an Alzheimer drug. The SUVN-502 molecule are intended to treat Alzheimer's disease, schizophrenia and other memory disorders.
The stock touched an intraday low of Rs 15.5 and subsequently touched a high of Rs 16.92 with trading volumes of 594,000 shares.